Enanta Pharmaceuticals, Inc.
ENTA
$13.85
$0.010.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 18.62M | 15.13M | 18.31M | 14.93M | 16.96M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.62M | 15.13M | 18.31M | 14.93M | 16.96M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 18.62M | 15.13M | 18.31M | 14.93M | 16.96M |
| SG&A Expenses | 9.01M | 9.70M | 10.00M | 11.39M | 12.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.87M | 33.51M | 37.21M | 39.45M | 40.50M |
| Operating Income | -11.25M | -18.39M | -18.89M | -24.53M | -23.54M |
| Income Before Tax | -11.91M | -18.67M | -18.23M | -23.95M | -22.71M |
| Income Tax Expenses | 24.00K | 32.00K | 29.00K | -1.31M | -416.00K |
| Earnings from Continuing Operations | -11.94M | -18.70M | -18.26M | -22.64M | -22.29M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.94M | -18.70M | -18.26M | -22.64M | -22.29M |
| EBIT | -11.25M | -18.39M | -18.89M | -24.53M | -23.54M |
| EBITDA | -10.02M | -17.10M | -17.68M | -23.32M | -22.65M |
| EPS Basic | -0.42 | -0.87 | -0.85 | -1.06 | -1.05 |
| Normalized Basic EPS | -0.26 | -0.57 | -0.53 | -0.70 | -0.65 |
| EPS Diluted | -0.42 | -0.87 | -0.85 | -1.06 | -1.05 |
| Normalized Diluted EPS | -0.26 | -0.57 | -0.53 | -0.70 | -0.65 |
| Average Basic Shares Outstanding | 28.75M | 21.38M | 21.38M | 21.36M | 21.24M |
| Average Diluted Shares Outstanding | 28.75M | 21.38M | 21.38M | 21.36M | 21.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |